- Home
- EXFY vs TERN Comparison
EXFY vs TERN Comparison
Compare EXFY & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXFY
- TERN
- Stock Information
- Founded
- EXFY 2008
- TERN 2017
- Country
- EXFY United States
- TERN United States
- Employees
- EXFY N/A
- TERN N/A
- Industry
- EXFY Computer Software: Prepackaged Software
- TERN Biotechnology: Pharmaceutical Preparations
- Sector
- EXFY Technology
- TERN Health Care
- Exchange
- EXFY Nasdaq
- TERN Nasdaq
- Market Cap
- EXFY 341.6M
- TERN 355.9M
- IPO Year
- EXFY 2021
- TERN 2021
- Fundamental
- Price
- EXFY $3.26
- TERN $4.01
- Analyst Decision
- EXFY Buy
- TERN Buy
- Analyst Count
- EXFY 4
- TERN 5
- Target Price
- EXFY $3.50
- TERN $18.30
- AVG Volume (30 Days)
- EXFY 342.6K
- TERN 1.7M
- Earning Date
- EXFY 02-27-2025
- TERN 03-13-2025
- Dividend Yield
- EXFY N/A
- TERN N/A
- EPS Growth
- EXFY N/A
- TERN N/A
- EPS
- EXFY N/A
- TERN N/A
- Revenue
- EXFY $137,440,000.00
- TERN N/A
- Revenue This Year
- EXFY N/A
- TERN N/A
- Revenue Next Year
- EXFY $6.06
- TERN N/A
- P/E Ratio
- EXFY N/A
- TERN N/A
- Revenue Growth
- EXFY N/A
- TERN N/A
- 52 Week Low
- EXFY $1.24
- TERN $3.96
- 52 Week High
- EXFY $4.13
- TERN $11.40
- Technical
- Relative Strength Index (RSI)
- EXFY 37.15
- TERN 33.73
- Support Level
- EXFY $3.31
- TERN $4.01
- Resistance Level
- EXFY $4.00
- TERN $4.24
- Average True Range (ATR)
- EXFY 0.23
- TERN 0.21
- MACD
- EXFY -0.06
- TERN 0.01
- Stochastic Oscillator
- EXFY 1.33
- TERN 5.59
About EXFY Expensify Inc.
Expensify Inc is a cloud-based expense management software platform that helps various businesses simplify the way to manage money. It is used to scan and reimburse receipts from flights, hotels, coffee shops, office supplies and ride shares. People use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases.